Literature DB >> 21792529

[Psychotropic drugs and diabetes].

Claudia Ress1, Alexander Tschoner, Susanne Kaser, Christoph F Ebenbichler.   

Abstract

Psychotropic drugs, such as antipsychotics and antidepressants, are widely used substances which can display marked metabolic side effects. Psychiatric patients display increased morbidity and mortality which, besides disease specific factors, may be attributed to metabolic side effects of psychotropic drugs. Commonly observed side effects of antipsychotics are weight gain as well as disturbances in glucose and lipid metabolism. Additionally, antipsychotics have been shown to increase diabetes risk. Also, the use of some of the antidepressant substances is associated with an increased diabetes risk. However, large inter-substance variations have been observed. Conversely, diabetics have an increased risk of depression. Metabolic side effects of psychotropic drugs pose a serious impairment for psychiatric patients and their management can play a pivotal role in therapeutic compliance and success. This review aims to give an overview of metabolic side effects of commonly used psychotic drugs and to give an insight into possible underlying mechanisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21792529     DOI: 10.1007/s10354-011-0004-9

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  110 in total

1.  Association of olanzapine-induced weight gain with an increase in body fat.

Authors:  U Eder; B Mangweth; C Ebenbichler; E Weiss; A Hofer; M Hummer; G Kemmler; M Lechleitner; W W Fleischhacker
Journal:  Am J Psychiatry       Date:  2001-10       Impact factor: 18.112

Review 2.  Antidepressants and body weight: a comprehensive review and meta-analysis.

Authors:  Alessandro Serretti; Laura Mandelli
Journal:  J Clin Psychiatry       Date:  2010-10       Impact factor: 4.384

3.  Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms.

Authors:  Hua Jin; David Folsom; Alana Sasaki; Sunder Mudaliar; Robert Henry; Monique Torres; Shah Golshan; Danielle K Glorioso; Dilip Jeste
Journal:  Schizophr Res       Date:  2010-11-19       Impact factor: 4.939

Review 4.  Experimental antipsychotics and metabolic adverse effects--findings from clinical trials.

Authors:  Alexander Tschoner; W Wolfgang Fleischhacker; Christoph F Ebenbichler
Journal:  Curr Opin Investig Drugs       Date:  2009-10

5.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich
Journal:  Lancet       Date:  2010-07-29       Impact factor: 79.321

Review 6.  The role of TNFalpha and TNF receptors in obesity and insulin resistance.

Authors:  G S Hotamisligil
Journal:  J Intern Med       Date:  1999-06       Impact factor: 8.989

7.  Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting.

Authors:  Glen L Xiong; Wei Jiang; Robert Clare; Linda K Shaw; Peter K Smith; Kenneth W Mahaffey; Christopher M O'Connor; K Ranga R Krishnan; L Kristin Newby
Journal:  Am J Cardiol       Date:  2006-05-05       Impact factor: 2.778

8.  National patterns in antidepressant medication treatment.

Authors:  Mark Olfson; Steven C Marcus
Journal:  Arch Gen Psychiatry       Date:  2009-08

9.  Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis.

Authors:  Lucy A Templeman; Gavin P Reynolds; Belen Arranz; Luis San
Journal:  Pharmacogenet Genomics       Date:  2005-04       Impact factor: 2.089

Review 10.  Health habits of patients with schizophrenia.

Authors:  Christiane Roick; Anita Fritz-Wieacker; Herbert Matschinger; Dirk Heider; Jana Schindler; Steffi Riedel-Heller; Matthias C Angermeyer
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-02-13       Impact factor: 4.519

View more
  2 in total

Review 1.  [Mental disorders and diabetes mellitus].

Authors:  Heidemarie Abrahamian; Alexandra Kautzky-Willer; Angelika Rießland-Seifert; Peter Fasching; Christoph Ebenbichler; Peter Hofmann; Hermann Toplak
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

2.  [Mental disorders and diabetes mellitus].

Authors:  Heidemarie Abrahamian; Alexandra Kautzky-Willer; Angelika Rießland-Seifert; Peter Fasching; Christoph Ebenbichler; Peter Hofmann; Hermann Toplak
Journal:  Wien Klin Wochenschr       Date:  2012-12       Impact factor: 1.704

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.